SCIENTIFIC OPINION

Inability to assess the safety of vitamin E-enriched yeast added for nutritional purposes as a source of vitamin E in food supplements and the bioavailability of vitamin E from this source, based on the supporting dossier ¹

Scientific Statement of the Panel on Food Additives and Nutrient Sources added to Food

(Question No EFSA-Q-2005-209)

Adopted on 4 June 2009

PANEL MEMBERS


¹ For citation purposes: Scientific Statement of the Panel on Food Additives and Nutrient Sources added to Food on the inability to assess the safety of vitamin E-enriched yeast added for nutritional purposes as a source of vitamin E in food supplements and the bioavailability of vitamin E from this source based on the supporting dossier following a request from the European Commission. The EFSA Journal (2009) 1123, 1-6.
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

The European Community legislation lists nutritional substances that may be used for nutritional purposes in certain categories of foods as sources of certain nutrients.

The Commission has received a request for the evaluation of vitamin E-enriched yeast added for nutritional purposes to food supplements. The relevant Community legislative measure is:


TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Commission asks the European Food Safety Authority to provide a scientific opinion, based on its consideration of the safety and bioavailability of vitamin E-enriched yeast added to food supplements.

STATEMENT

1. Introduction

Following a request from the European Commission to the European Food Safety Authority (EFSA), the Scientific Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to provide a scientific opinion on the safety of vitamin E-enriched yeast added for nutritional purposes as a source of vitamin E in food supplements and on the bioavailability of vitamin E from this source.

The vitamin E-enriched yeast is prepared with d-alpha tocopherol.

2. Summary of the information provided in the supporting dossier on vitamin E-enriched yeast

Vitamin E-enriched yeast is derived from cultures of specified strains of *Saccharomyces cerevisiae* grown in the presence of d-alpha tocopherol. Fermentation takes place at a specified temperature and pressure for defined periods of time. This is followed by increasing the temperature to kill the yeast. The cell wall is ruptured enzymatically to release the contents which are then spray dried.

The petitioner has provided some general information on the manufacturing process, but no details on the procedures used to produce vitamin E-enriched yeast are provided.

According to the petitioner, vitamin E in vitamin E-enriched yeast is naturally integrated by the growing yeast into its own structure and occurs therefore, in the way vitamin E would be present in any food material.

The petitioner states that during fermentation in the presence of vitamin E, a specific strain of *Saccharomyces cerevisiae* produces specific vitamin E compounds, the metabolic fate and the biological distribution of which are similar to those from other sources of vitamin E in the diet.

The petitioner states that “the integration will be chemically multi-formatted by the organism and therefore, its chemical name, formula, chemical family and CAS Registry Number is undefined”.

Comparative Fourier Transform Infrared (FTIR) spectra of the starter yeast, vitamin E, vitamin E-enriched yeast, and a simple mixture of yeast and vitamin E have been provided.

Vitamin E-enriched yeast is described as an amorphous hygroscopic cream-coloured powder with a slight yeast/citrus odour which is water soluble at 20 °C.

According to the petitioner, vitamin E is present at 16% of the source. The remaining 84% is made up of enzymatically ruptured yeast cells. The petitioner also provides microbiological specifications. Specifications for lead, mercury, cadmium and arsenic are not provided.

Specific proposals for use levels for vitamin E-enriched yeast were not provided. The petitioner only indicates that vitamin E-enriched yeast is to be used to provide a source of vitamin E supplied as a nutrient in food supplements. According to the petitioner the quantities added to the food supplements are product dependent, but because of the improved bioavailability are generally lower than those found in other sources of vitamin E.
Inability to assess the safety of vitamin E-enriched yeast as a source of vitamin E in food supplements

No data were provided on the bioavailability of the vitamin E from vitamin E-enriched yeast under consideration or on the safety of the source. Vinson et al., (1989) reported that rats fed an unspecified vitamin E enriched yeast product had 2.6 times more vitamin E in the liver than rats given uncomplexed vitamin E.

3. Assessment

The Panel notes that Saccharomyces cerevisiae has a qualified presumption of safety (EFSA, 2008) but considers that this presumption of safety might not be applicable to the specific conditions of culture of the yeast in the presence of a high quantity of vitamin E.

According to the petitioner fermentation in the presence of vitamin E within eukaryotic cells will produce vitamin E complexes not further defined, but with a metabolic fate and biological distribution similar to those of other sources of vitamin E in the diet.

According to the petitioner, from the comparative FTIR spectra it can be deduced that vitamin E is in ‘biological complex formation’ with yeast. The Panel considers that the FTIR spectra provided do not demonstrate the existence such complexes.

According to the petitioner, vitamin E from vitamin E-enriched yeast is safe. Although not explicitly stated in the dossier the argument for the safety of vitamin E-enriched yeast appears to be based on vitamin E being a normal constituent of the diet, and the long history of use of Saccharomyces cerevisiae in fermented food and beverages. The assumption is that, provided there is no overload of normal metabolic pathways, fermentation within eukaryotic cells will produce vitamin E complexes, the metabolic fate and the biological distribution of which are similar to those from other sources of vitamin E in the diet.

The Panel notes that the petitioner has insufficiently chemically characterised the product and therefore has not demonstrated that the vitamin E complexes have a metabolic fate and biological distribution similar to those of other sources of vitamin E in the diet.

The Panel also notes that it was not possible to assess the bioavailability of vitamin E from vitamin E-enriched yeast since neither data nor suitable supporting references were provided.

The Panel further notes that neither safety data nor suitable supporting references were provided to support the assumption of safety of vitamin E-enriched yeast.

CONCLUSIONS

The Panel concludes that due to the lack of an appropriate dossier supporting the use of vitamin E-enriched yeast in food supplements, the bioavailability of vitamin E from vitamin E-enriched yeast and the safety of vitamin E-enriched yeast cannot be assessed.
Key words:
Food supplements, vitamin E, d-alpha tocopherol, yeast-transformed vitamin E, vitamin E-enriched yeast

DOCUMENTATION PROVIDED TO EFSA

REFERENCES


ACKNOWLEDGEMENTS
Inability to assess the safety of vitamin E-enriched yeast as a source of vitamin E in food supplements

GLOSSARY / ABBREVIATIONS

ANS  Panel on Food Additives and Nutrient Sources added to Food
CAS  Chemical Abstracts Service
EC   European Commission
EFSA European Food Safety Authority
FT-IR Fourier Transform Infrared